Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Robert Dess MD

Robert T. Dess MD

Assistant Professor, Department of Radiation Oncology, University of Michigan, Ann Arbor Michigan; Prostate Cancer Co-Lead within the Michigan Radiation Oncology Quality Consortium (MROQC)


Dr. Dess is an Assistant Professor in the Department of Radiation Oncology at the University of Michigan. He attended medical school at University of Chicago and did his residency in radiation oncology at the University of Michigan where he joined the faculty upon completion of his training. He practices in several locations -- at the University of Michigan Ann Arbor main campus, where he leads the High Dose Rate (HDR) prostate brachytherapy program, and at the Brighton Center for Specialty Care as the primary genitourinary radiation oncologist.

Dr. Dess has published extensively in peer-reviewed journals on the topics of prostate, lung and breast cancer. His guiding principle is to deliver the right treatment to the right patient at the right time. To that end, he has worked with a rich network of collaborators to create novel prognostic models to characterize prostate cancer disease aggressiveness, to analyze racial outcomes differences and settings in which disparities are minimized, and to advance more convenient forms of treatment including stereotactic body radiation therapy (SBRT) and characterize long-term quality of life post-treatment. He is interested in maximizing efficacy, minimizing burden, and understanding the long-term toxicity risks of treatment.

Dr. Dess also serves as the co-lead for prostate cancer within the Michigan Radiation Oncology Quality Consortium (MROQC) where he works to improve state-wide care.


Dr. Dess has nothing to disclose.